Evaluation of Topical Chamomile Versus Topical Triamcinolone Acetonide in Management of Oral Lichen Planus

Overview

Using of herbal medications as topical chamomile which has antioxidant, anti-inflammatory and anticarcinogenesis effect with little side effects is the aim for the future treatment of OLP.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Outcomes Assessor)
  • Study Primary Completion Date: December 1, 2019

Detailed Description

Oral lichen planus (OLP) is a chronic inflammatory T cell mediated autoimmune disease that affects skin and any mucous membrane particularly oral mucosa.The patient complains of burning sensation, pain; interference with eating, swallowing and speech leading to worsening of quality of life.Oxidative stress plays a role in pathomechanism of OLP disease. Enzymatic and non- enzymatic anti-oxidants act as a physiological guard against reactive oxygen species (ROS) and cytokine-mediated toxicity.Herbal treatment is the aim of the future therapy.Chamomile has anti-oxidant , anti-inflammatory effect and accelerate healing.

Interventions

  • Drug: topical chamomile
    • herbal medication which has antioxidant, anti-inflammatory and anticarcinogenesis effect

Arms, Groups and Cohorts

  • Experimental: topical chamomile
    • herbal medication which has antioxidant, anti-inflammatory and anticarcinogenesis effect.
  • Active Comparator: Topical Triamcinolone Acetonide
    • topical triamcinolone acetonide is the gold standard treatment of oral lichen planus.

Clinical Trial Outcome Measures

Primary Measures

  • Pain using Numerical rating scale
    • Time Frame: 1 month
    • Pain measure using Numerical rating scale

Secondary Measures

  • clinical sign score
    • Time Frame: 1 month
    • Reduction in clinical sign score using Thongprasom et al

Participating in This Clinical Trial

Inclusion Criteria

  • Symptomatic OLP. – Patients with no history of taking corticosteroids for the last 6 months. – Patients who agree to take medication. – Medically free Exclusion Criteria:

  • Patients with oral lesions other than OLP. – Lichenoid reaction . – Pregnant females and lactation. – Smokers

Gender Eligibility: All

Minimum Age: 30 Years

Maximum Age: 80 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Cairo University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Esraa Nashat, 11 saraya st – manial – cairo – Cairo University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.